CA2131729A1 - Helicobacter pylori proteins useful for vaccines and diagnostics - Google Patents
Helicobacter pylori proteins useful for vaccines and diagnosticsInfo
- Publication number
- CA2131729A1 CA2131729A1 CA002131729A CA2131729A CA2131729A1 CA 2131729 A1 CA2131729 A1 CA 2131729A1 CA 002131729 A CA002131729 A CA 002131729A CA 2131729 A CA2131729 A CA 2131729A CA 2131729 A1 CA2131729 A1 CA 2131729A1
- Authority
- CA
- Canada
- Prior art keywords
- proteins
- helicobacter pylori
- pylori
- vaccines
- diagnostics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 241000590002 Helicobacter pylori Species 0.000 title abstract 2
- 229940037467 helicobacter pylori Drugs 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 101710112752 Cytotoxin Proteins 0.000 abstract 3
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 3
- 239000002619 cytotoxin Substances 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 1
- 102000006303 Chaperonin 60 Human genes 0.000 abstract 1
- 108010058432 Chaperonin 60 Proteins 0.000 abstract 1
- 206010061968 Gastric neoplasm Diseases 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 abstract 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 abstract 1
- 208000008469 Peptic Ulcer Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000010369 molecular cloning Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Helicobacter pylori is known to cause or be a cofactor in type B gastritis, peptic ulcers, and gastric tumors. In both deve-loped and developing countries, a high percentage of people are infected with this bacterium. The present invention relates gen-erally to certain H. pylori proteins, to the genes which express these proteins, and to the use of these proteins for diagnostic and vaccine applications. Specifically, molecular cloning, nucleotide, and amino acid sequences for the H. pylori cytotoxin (CT), the "Cytotoxin Associated Immunodominant" (CAI) antigen, and the heat shock protein (hsp60) are described herein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002383007A CA2383007A1 (en) | 1992-03-02 | 1993-03-02 | Helicobacter pylori proteins useful for vaccines and diagnostics |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITFI92A000052 | 1992-03-02 | ||
ITFI920052A IT1262895B (en) | 1992-03-02 | 1992-03-02 | Protein extracted from cytotoxic strains of Helicobacter pylori, gene expressing it, use of the protein as a vaccine or for diagnostic purposes. |
EPPCT/EP93/00158 | 1993-01-25 | ||
WOPCT/EP93/00158 | 1993-01-25 | ||
PCT/EP1993/000472 WO1993018150A1 (en) | 1992-03-02 | 1993-03-02 | Helicobacter pylori proteins useful for vaccines and diagnostics |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002383007A Division CA2383007A1 (en) | 1992-03-02 | 1993-03-02 | Helicobacter pylori proteins useful for vaccines and diagnostics |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2131729A1 true CA2131729A1 (en) | 1993-09-16 |
CA2131729C CA2131729C (en) | 2008-02-12 |
Family
ID=26069992
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002383007A Pending CA2383007A1 (en) | 1992-03-02 | 1993-03-02 | Helicobacter pylori proteins useful for vaccines and diagnostics |
CA002131729A Expired - Lifetime CA2131729C (en) | 1992-03-02 | 1993-03-02 | Helicobacter pylori proteins useful for vaccines and diagnostics |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002383007A Pending CA2383007A1 (en) | 1992-03-02 | 1993-03-02 | Helicobacter pylori proteins useful for vaccines and diagnostics |
Country Status (7)
Country | Link |
---|---|
US (3) | US6077706A (en) |
EP (1) | EP0967279B1 (en) |
JP (4) | JP3368902B2 (en) |
AU (1) | AU3630093A (en) |
CA (2) | CA2383007A1 (en) |
DE (2) | DE69334197T2 (en) |
WO (1) | WO1993018150A1 (en) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866375A (en) * | 1991-10-31 | 1999-02-02 | Chiron S.P.A. | Method for the culture of microorganisms of the genera helicobacter, campylobacter and arcobacter employing culture media comprising cyclodextrins |
ATE273021T1 (en) * | 1992-02-26 | 2004-08-15 | Univ Vanderbilt | PURIFIED VACUOLIZING TOXIN FROM HELICOBACTER PYLORI AND METHODS OF USE THEREOF |
US5721349A (en) * | 1992-02-26 | 1998-02-24 | Vanderbilt University | Vacuolating toxin-deficient H. pylori |
US5928865A (en) * | 1992-03-02 | 1999-07-27 | Chiron S.P.A. | Compositions comprising isolated Helicobacter pylori CagI polynucleotides and method of preparation thereof |
IT1262896B (en) * | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
MX9301706A (en) * | 1992-04-13 | 1994-05-31 | Oravax Inc | VACCINE COMPOSITION FOR THE TREATMENT OF HELICOBACTER INFECTION. |
US5403924A (en) * | 1992-10-13 | 1995-04-04 | Vanderbilt University | Taga gene and methods for detecting predisposition to peptic ulceration |
US5733740A (en) * | 1992-10-13 | 1998-03-31 | Vanderbilt University | Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma |
US5972336A (en) * | 1992-11-03 | 1999-10-26 | Oravax Merieux Co. | Urease-based vaccine against helicobacter infection |
US6290962B1 (en) * | 1992-11-03 | 2001-09-18 | Oravax, Inc. | Urease-based vaccine and treatment for helicobacter infection |
JPH08509873A (en) * | 1993-05-19 | 1996-10-22 | アンスティテュ・パストゥール | Immune composition against Helicobacter infection, polypeptide used in the composition and nucleic acid sequence encoding the polypeptide |
US5843460A (en) * | 1993-05-19 | 1998-12-01 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides |
GB9313279D0 (en) * | 1993-06-28 | 1993-08-11 | Medical Res Council | Protection against infection with helicobacter pylori |
US6406703B1 (en) | 1993-07-27 | 2002-06-18 | Csl Limited | Treatment of H. pylori associated gastroduodenal disease |
US5871749A (en) * | 1993-07-27 | 1999-02-16 | Csl Limited | Therapeutic treatment of H. pylori associated gastroduodenal disease |
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5997873A (en) * | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
GB2290710B (en) * | 1994-06-29 | 1998-03-25 | Reckitt & Colmann Prod Ltd | Protease from helicobacter pylori for use in vaccines/therapeutic compositions |
GB2303854B (en) * | 1994-07-01 | 1998-10-21 | Rican Limited | Helicobacter proteins and vaccines |
GB9505438D0 (en) * | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
WO1997003359A1 (en) * | 1995-07-07 | 1997-01-30 | Oravax, Inc. | Helicobacter clpb |
US5837251A (en) * | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5985270A (en) * | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
JPH11502418A (en) * | 1995-10-09 | 1999-03-02 | パストゥール メリユ セリュム エ ヴァサン | Helicobacter lactoferrin receptor |
ES2283012T3 (en) * | 1996-01-04 | 2007-10-16 | Novartis Vaccines And Diagnostics, Inc. | HELICOBACTER PYLORI BACTERIOFERRITINE. |
JPH1033179A (en) * | 1996-07-24 | 1998-02-10 | Fuso Yakuhin Kogyo Kk | Probe for diagnosis of infectious disease |
WO1998012562A1 (en) * | 1996-09-20 | 1998-03-26 | Cortecs International Limited | Adhesins from heliobacter pylori and their diagnostic and therapeutic uses |
AU5697898A (en) * | 1996-12-19 | 1998-07-15 | Chiron Corporation | (helicobacter pylori) diagnostics |
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
AU751433B2 (en) * | 1997-04-30 | 2002-08-15 | Merieux Oravax | Anti-(helicobacter) vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method |
FR2748477B1 (en) * | 1997-07-01 | 2001-07-13 | Pasteur Merieux Serums Vacc | NEW MEMBRANE PROTEIN OF HELICOBACTER PYLORI |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
AU1866099A (en) * | 1997-12-31 | 1999-07-26 | Stressgen Biotechnologies Corporation | Streptococcal heat shock proteins of the hsp60 family |
CA2330313C (en) * | 1998-04-30 | 2012-09-18 | Chiron S.P.A. | Immunization against and treatment for infection by h.pylori |
US6585975B1 (en) * | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
US6838553B1 (en) * | 1999-10-05 | 2005-01-04 | Academia Sinica | Peptide repeat immunogens |
GB9924060D0 (en) * | 1999-10-11 | 1999-12-15 | Chiron Spa | VIP54 protein |
ES2541830T3 (en) | 1999-10-29 | 2015-07-27 | Novartis Vaccines And Diagnositics S.R.L. | Neisseria antigenic peptides |
PT1248647E (en) | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins |
US7449557B2 (en) | 2000-06-02 | 2008-11-11 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
US20020107368A1 (en) * | 2000-12-07 | 2002-08-08 | Jing-Hui Tian | Helicobacter proteins, gene sequences and uses thereof |
CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
JP4384489B2 (en) | 2001-08-20 | 2009-12-16 | ユニバーシティー オブ コネティカット ヘルス センター | Method for preparing a composition comprising a heat shock protein or α-2-macroglobulin useful for the treatment of cancer and infectious diseases |
CA2476626A1 (en) | 2002-02-20 | 2003-08-28 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
US20050250175A1 (en) * | 2002-08-02 | 2005-11-10 | Takehiko Nomura | Bacterial cell wall skeleton component preparaion |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
EP1556477B1 (en) | 2002-11-01 | 2017-08-09 | GlaxoSmithKline Biologicals s.a. | Drying process |
ATE466875T1 (en) | 2002-11-15 | 2010-05-15 | Novartis Vaccines & Diagnostic | UNEXPECTED SURFACE PROTEINS IN NEISSERIA MENINGITIDIS |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
EP1608369B1 (en) | 2003-03-28 | 2013-06-26 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
CA2528007C (en) | 2003-06-02 | 2012-03-27 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
EP1654283B1 (en) | 2003-08-13 | 2011-07-13 | Novartis Vaccines and Diagnostics, Inc. | Improved method of purifying tfpi and tfpi analogs |
EP1730171A1 (en) | 2004-02-19 | 2006-12-13 | Ramot at Tel Aviv University Ltd. | Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof |
JP5041279B2 (en) * | 2004-04-22 | 2012-10-03 | 株式会社 Mbr | Formulation containing bacterial cell wall skeleton component |
DE602005017391D1 (en) | 2004-06-24 | 2009-12-10 | Yissum Res Dev Co | USE OF PEPTIDE MIMOTOPES OF MANNOSYLATED LIPOGLYCANES FROM MYCOBACTERIA FOR THE TREATMENT OF INFLAMMATION |
WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
CA2571421A1 (en) | 2004-06-24 | 2006-01-05 | Nicholas Valiante | Compounds for immunopotentiation |
EP1784211A4 (en) | 2004-07-29 | 2010-06-30 | Novartis Vaccines & Diagnostic | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
EP1838340B1 (en) | 2004-12-22 | 2018-04-04 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
US20110223197A1 (en) | 2005-10-18 | 2011-09-15 | Novartis Vaccines And Diagnostics Inc. | Mucosal and Systemic Immunization with Alphavirus Replicon Particles |
US7527801B2 (en) | 2005-11-22 | 2009-05-05 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and Sapovirus antigens |
ES2536426T3 (en) | 2006-03-23 | 2015-05-25 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
KR100846494B1 (en) * | 2006-09-26 | 2008-07-17 | 삼성전자주식회사 | Primer set for amplifying target sequences of Helicobacter pylori method for detecting Helicobacter pylori using the primer set and kit for detecting Helicobacter pylori comprising the primer set |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
WO2009034473A2 (en) | 2007-09-12 | 2009-03-19 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
RU2498994C2 (en) | 2007-12-21 | 2013-11-20 | Новартис Аг | Mutant shapes of o-streptolysin |
CA2732763A1 (en) | 2008-08-01 | 2010-02-04 | Cleveland Biolabs, Inc. | Methods for treating reperfusion injuries |
EP2331127A2 (en) | 2008-09-18 | 2011-06-15 | Novartis AG | Vaccine adjuvant combinations |
CN103897045A (en) | 2009-01-12 | 2014-07-02 | 诺华股份有限公司 | Cna_b domain antigens in vaccines against gram positive bacteria |
CN102740882A (en) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | Adjuvant comprising aluminium, oligonucleotide and polycation |
CA2772916C (en) | 2009-09-02 | 2019-01-15 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
CN102933267B (en) | 2010-05-28 | 2015-05-27 | 泰特里斯在线公司 | Interactive hybrid asynchronous computer game infrastructure |
EP2719395A1 (en) | 2010-09-01 | 2014-04-16 | Novartis AG | Adsorption of immunopotentiators to insoluble metal salts |
WO2012082914A1 (en) | 2010-12-14 | 2012-06-21 | Novartis Ag | Flow cytometry analysis of materials adsorbed to metal salts |
EA026524B1 (en) | 2011-01-10 | 2017-04-28 | Общество С Ограниченной Ответственностью "Биолаб 612" | USE OF Toll-LIKE RECEPTOR AGONIST FOR TREATING CANCER |
CN103533954B (en) | 2011-03-02 | 2015-09-09 | 诺华股份有限公司 | Contain compared with the antigen of low dosage and/or the combined vaccine of adjuvant |
WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
PT2822947T (en) | 2012-03-07 | 2016-09-26 | Glaxosmithkline Biologicals Sa | Arginine salts of a tlr7 agonist |
RU2014140521A (en) | 2012-03-08 | 2016-04-27 | Новартис Аг | ADJUVANT COMPOSITIONS OF BOOSTER VACCINES |
EP2877852B1 (en) * | 2012-07-23 | 2022-05-25 | Hermouet, Sylvie | A protein microarray for characterizing the specificity of the monoclonal immunoglobulins of mgus or myeloma patients |
ES2816630T3 (en) | 2014-07-30 | 2021-04-05 | Genome Prot Inc | Flagellin compositions and uses |
EP3206708B1 (en) | 2014-10-16 | 2022-11-02 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
SE541618C2 (en) * | 2017-02-24 | 2019-11-12 | Biotome Pty Ltd | Novel peptides and their use in diagnosis |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3751307T2 (en) | 1986-03-28 | 1995-09-21 | Univ Illinois | PREPARATIONS AND METHODS FOR CLONES CONTAINING DNA SEQUENCES IN HUMAN CELLS ASSOCIATED WITH MULTIPLE MEDICINE RESISTANCE. |
US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
US5459041A (en) * | 1988-02-18 | 1995-10-17 | Enteric Research Laboratories, Inc. | Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection |
US4882271A (en) * | 1988-03-10 | 1989-11-21 | Baylor College Of Medicine | Process for preparation of high molecular weight cell-associated protein of campylobacter pylori and use for serological detection of campylobacter pylori infection |
FR2637612B1 (en) * | 1988-10-06 | 1993-09-10 | Pasteur Institut | NUCLEOTIDE SEQUENCES ENCODING A PROTEIN WITH UREASIC ACTIVITY |
AU640118B2 (en) | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
GB8928625D0 (en) * | 1989-12-19 | 1990-02-21 | 3I Res Expl Ltd | H.pylori dna probes |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
ES2198514T3 (en) | 1991-08-27 | 2004-02-01 | F. Hoffmann-La Roche Ag | PRIMERS AND PROBES FOR THE DETECTION OF HEPATITIS C. |
US5354854A (en) | 1991-11-07 | 1994-10-11 | The Curators Of The University Of Missouri | Expression system for use in plants to suppress foreign expression and method |
US5721349A (en) * | 1992-02-26 | 1998-02-24 | Vanderbilt University | Vacuolating toxin-deficient H. pylori |
IT1262895B (en) | 1992-03-02 | 1996-07-22 | Protein extracted from cytotoxic strains of Helicobacter pylori, gene expressing it, use of the protein as a vaccine or for diagnostic purposes. | |
US5403924A (en) * | 1992-10-13 | 1995-04-04 | Vanderbilt University | Taga gene and methods for detecting predisposition to peptic ulceration |
US5733740A (en) | 1992-10-13 | 1998-03-31 | Vanderbilt University | Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma |
US6019982A (en) * | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
US6902903B1 (en) | 1996-12-19 | 2005-06-07 | Chiron Corporation | Helicobacter pylori diagnostics |
CA2408328C (en) | 2000-05-10 | 2012-04-17 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
-
1993
- 1993-03-02 CA CA002383007A patent/CA2383007A1/en active Pending
- 1993-03-02 AU AU36300/93A patent/AU3630093A/en not_active Abandoned
- 1993-03-02 DE DE69334197T patent/DE69334197T2/en not_active Expired - Lifetime
- 1993-03-02 WO PCT/EP1993/000472 patent/WO1993018150A1/en active IP Right Grant
- 1993-03-02 DE DE69333110T patent/DE69333110T2/en not_active Expired - Lifetime
- 1993-03-02 EP EP99202698A patent/EP0967279B1/en not_active Expired - Lifetime
- 1993-03-02 CA CA002131729A patent/CA2131729C/en not_active Expired - Lifetime
- 1993-03-02 JP JP51530993A patent/JP3368902B2/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/470,260 patent/US6077706A/en not_active Expired - Lifetime
-
2000
- 2000-04-26 JP JP2000126696A patent/JP2000333686A/en active Pending
- 2000-04-26 JP JP2000126695A patent/JP3408494B2/en not_active Expired - Lifetime
-
2001
- 2001-08-02 US US09/921,157 patent/US20040048353A1/en not_active Abandoned
-
2003
- 2003-07-08 US US10/615,668 patent/US7700755B2/en not_active Expired - Fee Related
-
2005
- 2005-09-09 JP JP2005263068A patent/JP2006055168A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU3630093A (en) | 1993-10-05 |
DE69333110D1 (en) | 2003-08-28 |
JP2000333686A (en) | 2000-12-05 |
US20050276819A1 (en) | 2005-12-15 |
DE69334197D1 (en) | 2008-02-14 |
US7700755B2 (en) | 2010-04-20 |
EP0967279B1 (en) | 2008-01-02 |
DE69334197T2 (en) | 2008-12-11 |
US20040048353A1 (en) | 2004-03-11 |
JPH07504565A (en) | 1995-05-25 |
JP3368902B2 (en) | 2003-01-20 |
JP2000350591A (en) | 2000-12-19 |
US6077706A (en) | 2000-06-20 |
EP0967279A1 (en) | 1999-12-29 |
CA2131729C (en) | 2008-02-12 |
CA2383007A1 (en) | 1993-09-16 |
JP3408494B2 (en) | 2003-05-19 |
WO1993018150A1 (en) | 1993-09-16 |
JP2006055168A (en) | 2006-03-02 |
DE69333110T2 (en) | 2004-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2131729A1 (en) | Helicobacter pylori proteins useful for vaccines and diagnostics | |
NO20070618L (en) | Compounds and Methods for Immunotherapy and Diagnosis of Tuberculosis. | |
MY119003A (en) | Bacterial antigens and vaccine compositions | |
SG48353A1 (en) | Helicobacter pylori proteins useful for vaccines and diagnostics | |
EP2168596A3 (en) | Immunisation against chlamydia trachomatis | |
HK1080506A1 (en) | Fusion proteins of mycobacterium tuberculosis | |
AU2001276619A1 (en) | Immunisation against chlamydia pneumoniae | |
EA007409B1 (en) | Streptococcus antigen polypeptides, methods of producing and use thereof | |
WO1995029193A3 (en) | Melanoma antigens | |
US20090035259A1 (en) | Group a streptococcal vaccines | |
BR9906927A (en) | Neisseria meningitidis proteins | |
AU4545889A (en) | Synthetic dna derived recombinant hiv antigens | |
NO883763D0 (en) | THERAPEUTIC MIXTURES AGAINST STRIPTOCOCCIN INFECTIONS, TRANSFORMED HOSTS, IMMUNIZATION PROCEDURES, AND REPLACEMENT PRODUCTS. | |
AU2191597A (en) | Vmp-like sequences of pathogenic borrelia | |
HU9401511D0 (en) | Vaccine against streptococcus suls infection | |
KR970703165A (en) | Vaccine against mycobacterial infection (VACCINE AGAINST MYCOBACTERIAL INFECTIONS) | |
AU9388498A (en) | Group a streptococcal vaccines | |
DK0892054T3 (en) | Clostridium perfringens vaccine | |
AU2667600A (en) | Identification of specific differentially expressed antigens | |
NZ512448A (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
EP1801217A1 (en) | Group A streptococcal vaccines | |
EP1009764A1 (en) | VACCINE COMPOSITIONS COMPRISING THE $i(HELICOBACTER PYLORI) FlgE POLYPEPTIDE | |
NZ512308A (en) | Chlamydia antigens and corresponding DNA fragments and uses thereof | |
EP0949333A4 (en) | Mutant measles virus antigens and genes encoding the same | |
MXPA99011528A (en) | Vaccine compositions comprising the helicobacter pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |